Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis

NCT07904754 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07904754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 7, 2026
Completion date
July 31, 2029
Enrollment
250 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis

Arms

As registered; 5 arms.

  • ABBV-2294 Dose A ExperimentalABBV-722, Upadacitinib

    Participants will receive co-administration of ABBV-722 and upadacitinib

  • ABBV-2294 Dose B ExperimentalABBV-722, Upadacitinib

    Participants will receive co-administration of ABBV-722 and upadacitinib

  • ABBV-2294 Dose C ExperimentalABBV-722, Upadacitinib

    Participants will receive co-administration of ABBV-722 and upadacitinib

  • ABBV-722 Monotherapy ExperimentalABBV-722

    Participants will receive ABBV-722. At Week 12, participants will then be blindly switched to co-administration of ABBV-722 and upadacitinib.

  • Upadacitinib Monotherapy Active comparatorUpadacitinib

    Participants will receive upadacitinib.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Percentage of Participants Achieving ACR50 Response Week 12

    The ACR50 response is defined as at least 50% improvement in the American College of Rheumatology (ACR) criteria for rheumatoid arthritis. The ACR50 response requires at least 50% improvement in tender and swollen joint counts and at least 50% improvement in at least 3 of the following 5 measures: patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function (HAQ-DI), and acute phase reactant (CRP or ESR).

  • Number of Participants Experiencing Adverse Events Up to 80 Weeks

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Lead sponsor's other trials

AbbVie, most recent start first.

Similar trials

Same condition (Arthritis, Rheumatoid) and phase, most recent start first.